Adamas Pharmaceuticals, Inc.
1900 Powell Street
Suite 1050
Emeryville
California
94608
United States
Tel: 510-450-3500
Fax: 510-428-0519
Website: http://www.adamaspharma.com/
Email: info@adamaspharma.com
About Adamas Pharmaceuticals, Inc.
200 articles about Adamas Pharmaceuticals, Inc.
-
ADMS INVESTOR DEADLINE IN 7 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc.
2/3/2020
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) between August 8, 2017, and September 30, 2019, inclusive (the “Class Period”)
-
Adamas Announces New Employment Inducement Grant - Jan. 10, 2020
1/10/2020
Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 12,000 shares of the company’s common stock, at a per share exercise price of $5.11, the closing trading price on January 8, and restricted stock units to acquire 6,000 shares of the company’s common stock.
-
Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020
1/8/2020
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today provides preliminary unaudited fourth quarter and full year 2019 product sales for GOCOVRI® (amantadine) extended release capsules and outlines key business priorities for 2020.
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
Adamas Pharmaceuticals reported that its Phase III INROADS trial of Gocovri (ADS-5102) for multiple sclerosis (MS) with walking impairment met its primary endpoint. That would seem to be good news, but the trial failed to meet secondary measures which worried investors, causing shares to drop by ...
-
Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment
12/17/2019
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that INROADS, a 3-arm, randomized, double-blind, placebo-controlled study in 594 multiple sclerosis (MS) patients with walking impairment met its primary endpoint.
-
ADMS LOSS NOTICE ALERT: TOP RANKED Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. - ADMS
12/14/2019
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017 and September 30, 2019, inclusive.
-
ADMS INVESTOR ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Adamas Pharmaceuticals, Inc.
12/12/2019
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017, and September 30, 2019, inclusive.
-
Adamas Announces New Employment Inducement Grant - Dec. 09, 2019
12/9/2019
Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 89,000 shares of the company’s common stock, at a per share exercise price of $6.48, the closing trading price on December 6, and restricted stock units to acquire 44,500 shares of the company’s common stock.
-
Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
11/21/2019
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the following investor conferences:
-
Adamas Reports Third Quarter 2019 Financial Results
11/7/2019
Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019
-
Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
10/30/2019
Adamas Pharmaceuticals, Inc. announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close.
-
Lifshitz & Miller LLP Announces Investigation of Adamas Pharmaceuticals, Inc., ASGN Inc, Box, Inc., ChinaCache International Holdings Ltd, Mammoth Energy Services, Inc., Realogy Holdings Corp., Total System Services, Inc., and Verint Systems
6/27/2019
Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Adamas faced significant roadblocks that would drastically reduce its ability to sell Gocovro.
-
Clinical Catch-Up for June 17-21
6/24/2019
Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories. -
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease- New analysis of GOCOVRI™ (amantadine) extended release capsules pooled Phase 3 data
10/4/2018
Adamas Pharmaceuticals, Inc. today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules were published online in Parkinsonism and Related Disorders
-
Pre-Market Research Reports on Generic Drugs Stocks -- Tricida, Zoetis, Adamas Pharma, and Allergan
7/23/2018
On Friday, key US indices were bearish as the NASDAQ Composite finished the trading session down 0.07%; the Dow Jones Industrial Average edged 0.03% lower; and the S&P 500 was down 0.09%.
-
Adamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018
2/14/2018
The management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
-
Adamas Announces New Employment Inducement Grant - Feb. 12, 2018
2/12/2018
The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan.
-
Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
2/8/2018
The safety and tolerability profile of these patients was consistent with prior controlled studies.
-
Adamas Announces Publication of ADS-5102 Phase II Clinical Trial Results in Multiple Sclerosis Journal
2/2/2018
Placebo-controlled proof-of-concept trial demonstrated that ADS-5102 significantly improved walking speed in multiple sclerosis patients with walking impairment.